Figures
Abstract
Transforming growth factor (TGF)-β1 is known to play a pivotal role in a diverse range of biological systems including modulation of fibrosis in several organs. The precise role of TGF-β/Smad signaling in the progression of bladder fibrosis secondary to partial bladder outlet obstruction (PBOO) is yet to be conclusively. Using a rat PBOO model, we investigated TGF-β1 expression and exaimined whether sodium tanshinone IIA sulfonate (STS) could inhibit TGF-β/Smad signaling pathway activation and ameliorate bladder fibrosis. Forty-eight female Sprague-Dawley rats were randomly divided into three groups: sham operation group (n = 16), PBOO operation without STS treatment group (n = 16) and PBOO operation with STS treatment group (n = 16). Thirty-two rats underwent the operative procedure to create PBOO and subsequently received intraperitoneal injections of STS (10 mg/kg/d; n = 16) or vehicle (n = 16) two days after the surgery. Sham surgery was conducted on 16 rats, which received intraperitoneal vehicle injection two days later. In each of the three groups, an equal number of rats were sacrificed at weeks 4 and 8 after the PBOO or sham operation. The TGF-β/Smad signaling pathway was analyzed using western blotting, immunohistochemical staining and reverse transcriptase polymerase chain reaction (RT-PCR). One-way analysis of variance was conducted to draw statistical inferences. At 4 and 8 weeks, the expression of TGF-β1 and phosphorylated Smad2 and Smad3 in STS-treated PBOO rats was significantly lower than in the PBOO rats not treated with STS. Alpha smooth muscle actin (α-SMA), collagen I and collagen III expression at 4 and 8 weeks post PBOO was lower in STS-treated PBOO rats when compared to that in PBOO rats not treated with STS. Our findings indicate that STS ameliorates bladder fibrosis by inhibiting TGF-β/Smad signaling pathway activation, and may prove to be a potential therapeutic measure for preventing bladder fibrosis secondary to PBOO operation.
Citation: Jiang X, Chen Y, Zhu H, Wang B, Qu P, Chen R, et al. (2015) Sodium Tanshinone IIA Sulfonate Ameliorates Bladder Fibrosis in a Rat Model of Partial Bladder Outlet Obstruction by Inhibiting the TGF-β/Smad Pathway Activation. PLoS ONE 10(6): e0129655. https://doi.org/10.1371/journal.pone.0129655
Academic Editor: Utpal Sen, University of Louisville, UNITED STATES
Received: December 22, 2014; Accepted: May 12, 2015; Published: June 10, 2015
Copyright: © 2015 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper.
Funding: This study was funded by Xuzhou Municipal Science and Technology development grant XF11C066.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Partial urinary bladder outlet obstruction (PBOO) is frequently observed in various clinical diseases such as benign prostate hyperplasia (BPH), neurogenic bladder, bladder neck stricture or posterior urethral stenosis. Bladder function is altered following bladder outlet obstruction and cannot be restored entirely, even after the obstruction is relieved. The characteristics of PBOO include bladder smooth muscle hyperplasia, increased strength of detrusor contractility, or deposition of extracellular matrix (ECM)[1]. Bladder tissue fibrosis is an inevitable consequence of excessive ECM accumulation that occurs virtually in all cases of chronic bladder outlet obstruction. The development of bladder wall tissue fibrosis in the setting of partial outlet obstruction is thought to be due to increased levels of nerve growth factor, basic fibroblast growth factor, connective tissue growth factor or transforming growth factorβ1(TGF-β1)[2–5].
Among the diverse regulatory factors involved, TGF-β1 might play a critical role in bladder fibrosis. Transforming growth factor-β1, a dimmer, composed of two equal subunits containing 112 amino acids, is a multifunctional growth factor. It initiates intracellular responses by binding to the specific transmembrane receptors which have intracellular serine/threonine kinase activity[6]. These activated receptors further lead to phosphorylation of receptor-associated Smad2/3 proteins, which are capable of combining with Smad4. Finally, this complex of activated receptors and proteins regulates the transcription of target genes. A study using a 6-week bladder outlet obstruction model, demonstrated increase in the the weight of bladder tissue and decrease in that the detrusor contractile force, which was accompanied by a significant increase in urine TGF-β1 [7]. The study reported a negative correlation between urine TGF-β1 levels and detrusor contractile force. In a study conducted by Anumanthan et al., bladder compliance was found to be increased in partially obstructed TGF-β type II receptor knockout mice, with decreased collagen deposition[8]. Blockage of the TGF-β/Smad signaling pathway by using various strategies such as anti-transforming growth factor (TGF)-β1 antibody, tanshinone II A, microRNAs and small interfering RNA have provided vital evidence pointing towards the crucial role of the pathway in development of fibrosis in various tissues and organs [9–12].
Sodium tanshinone IIA sulfonate (STS) is a water-soluble compound extracted from the root of a Chinese herbal Salvia miltiorrhiza Bunge. It has been widely used in traditional Chinese medicine for treating cardiovascular diseases, inflammatory disorders, and hepatitis [10, 13, 14]. While accumulated evidence shows that STS inhibits tissue or organ fibrosis, the definite mechanism by which this occurs is a major topic of discussion. Various studies have demonstrated that STS ameliorates cardiac, renal and atrial fibrosis by TGF-β1 signaling [10, 15, 16]. TGF-β1 is also thought to play a pivotal role in the deterioration of the bladder tissue fibrosis that follows PBOO. The present study was conducted to assess whether STS prevents the development of bladder fibrosis by inhibiting the TGF-β/Smad signaling pathway in a rat PBOO model.
Materials and Methods
Animals and animal models of partial bladder outlet obstruction (PBOO)
Adult female Sprague Dawley rats weighing 160-200g were obtained from the Experimental Animal Centre of the Xuzhou Medical College (Xuzhou, China). This study was approved by Xuzhou Medical College Committee for Animal Experimentation. All animal experiments were performed in accordance with the guidelines set by Xuzhou Medical College Committee for Animal Experimentation (Permit Number: S2010-0011). The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were housed in a temperature controlled room, maintained between 21°C and 25°C, exposed to a 12 hour light–dark cycle, and had free access to food and water.
Forty eight adult female Sprague-Dawley rats were randomly divided into three groups: sham operation group (n = 16), PBOO operation without STS treatment group (n = 16) and PBOO operation with STS treatment group (n = 16). In our study, the PBOO procedure performed was a slightly modified version of the technique described previously[17]. The animals were anaesthetized using intraperitoneal injection of sodium pentobarbital (Sigma, 40 mg/kg). After disinfection with iodine tincture, a catheter of 1mm diameter was inserted into the urethra, A midline incision was made on the abdominal to expose the urethrovesical junction. The proximal urethra was tied gently but snugly around the urethrovesical junction with a 3–0 silk thread, the incision was closed, and the catheter was removed to produce PBOO. Gentamicin (0.1 mg/kg) was administered intraperitoneally. The same procedure was conducted on the rats in the sham group, but without applying the ligature around the proximal urethra. The rats in the sham operation group and PBOO operation without STS treatment group were injected intraperitoneally with sterile normal saline two days post operation, while the rats in PBOO operation with STS treatment group received intraperitoneal injection of STS (10mg/kg/d, Shanghai NO.1 Biochemical& Pharmaceutical Co., Ltd, China)[18]. All drugs were dissolved in normal saline and injected intraperitoneally. Half of the rats in each of the three groups were sacrificed in four weeks after the procedure, while the remaining half were sacrificed eight weeks post-procedure the remaining. After the sacrifice, part of the bladder tissues were immediately harvested for histology or immunochemistry, and the remaining tissues were stored in liquid nitrogen for performing in RT-PCR or western blotting.
Histological and immunohistochemical measurements
Bladder tissues fixed in 4% buffered paraformaldehyde solution were embedded in paraffin and cut into 4μm sections. The sections were stained with Masson’s trichrome staining kit (KeyGen Biotech, Nanjin, China) and hematoxylin and eosin staining for histological analysis and assessment of interstitial collagen content. Immunohistochemical assays were performed by using anti-TGFβ1 (Santa Cruz Technology, USA), anti-phospho-Smad2 (Bioworld Technology, USA), anti-phospho-Smad3 (Cell signaling), anti-collagen-I (Bioworld Technology, USA), anti-collagen III (Bioworld Technology, USA), and anti-a-SMA (Santa Cruz Technology, USA). The sections were dewaxed and quenched with 3% hydrogen peroxide for 10minutes to block the endogenous peroxidase activity, followed by serum-free protein blocking (ZSGB-BIO, Beijing, China). The sections were then incubated with various antibody mentioned above, followed by incubation with biotinylated anti-rat IgG and HRP-Streptavidin (ZSGB-BIO, Beijing, China). Diaminobenzidine was used as a substrate and counterstaining was performed with hematoxylin. A negative control was prepared by using an irrelevant IgG. Four fields were randomlyselected from each sample and examined under light microscopy (400x magnifiation) and the evaluator was blinded to the identity of the group of rats from which the sections were prepared to avoid an bias. The results of immunochemistry were analyzed by using an image analyze software (Image J, Institutes of Health).
Western blotting
Western blotting was performed for the detection of TGFβ1, smad2/3, phosphorylated Smad2/3, a-SMA, collagen I and collagen III. Total proteins were extracted from bladder tissues and analyzed with bicinchoninic acid protein concentration assay kit (Beyotime Institutes of Biotechnology, Shanghai, China). Proteins were isolated from the samples by SDS-PAGE electrophoresis and then transferred onto nitrocellulose membrane. After blocking with 5% nonfat milk or 2% bovine serum albumin (BSA), the membranes were incubated at 4°C overnight with a rabbit anti-rat polyclonal TGFβ1 (Santa Cruz Technology, 1:800dilution), smad2/3 antibody (Santa Cruz Technology, 1:1000dilution), p-smad2 antibody (Bioword Technology, 1:800dilution), p-smad3 (Cell signaling,1:1000dilution), α-SMA(Cell signaling,1:1000dilution), collagen I (Bioworld Technology, 1:800dilution) and collagen III (Bioworld Technology,1:800dilution). The second antibody was a goat anti-rabbit IgG (1:10000dilution, Li-COR, USA), which was diluted in TBST. Signals were scanned and visualized by Odyssey Infrared Imaging System (LiCor Inc., Lincoln, NE). Density of western strap was quantified by Image J software, with the gray value representing the amount of expressed target protein. Relative protein levels were calculated by comparing the gray value of target protein to the amount of β-actin protein.
Real-time reverse transcriptase polymerase chain reaction
Total RNA was extracted from the frozen bladder tissues using Trizol Reagent(Tiangen Biotech Co.,Ltd. Beijing, China) in accordance with the vendor’s instructions. First strand cDNA was synthesized using Oligo(dT)15 primers in a first strand synthesis kit (Promega Tech, Co., Ltd, USA). Real-time PCR was conducted using PCR Master Mix (Promega Tech, Co., Ltd, USA) according to the vendor’s recommendations. Total RNA was reverse-transcribed and subjected to PCR as follows: 95°C for 2minutes followed by 30 cycles, each cycle comprising of 95°C for 30s, 56°C for 30s and 72°C for 45s,and a final extension at 72°C for 7minutes.The primer sequences amplified were as follows.
- Rat TGFβ1: sense: 5’-CCGCAACAACGCAATCTA-3’, anti-sense: 5’-TGAGGAGCAGGAAGGGTC -3’
- Smad2: sense: 5’-CCACTACCAGAGGGTGGAGA-3’, anti-sense: 5’-TAACTG GCTGCAATCCAAG-3’
- α-SMA: sense: 5’-CTGAGCGTGGCTATTCCTTC-3’, anti-sense: 5’-CGTCATACTCCTGTTTGCTGA-3’;
- Smad3: sense 5’-AACTGCAGT GCCGCTATCC -3’, anti-sense: 5’- CCAGCGGGGAAGTTAGTGTT-3’
- Collagen1: sense 5’-ATCAGCCCAAACCCCAAGGAGA-3’, anti-sense: 5’-CGCAGGAAGGT CAGCTGGATAG-3’
Collagen 3: sense 5’-TGATGGGATCCAATGAGGGAGA-3’, anti-sense: 5’-GAG TCT CATGGCCTTGCGTGTTT-3’
Primer sequences for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 5’-CGTCATTGACCTCAACTACATG-3’ (sense) and 5’-CTTCTCC ACGGTGGTGAAGAC-3’ (anti-sense) as an internal standard. Reverse-transcribed PCR products were detected by 2% agarose gel electrophoresis. Expression levels of target mRNA were represented by ratios of TGFβ1/ GAPDH, Smad2/ GAPDH, Smad3/ GAPDH, α-SMA/ GAPDH, Collagen1/ GAPDH, Collagen3/ GAPDH mRNA and showed as the mean ±S.D.
Results
Effects of STS on bladder tissue histology in rat PBOO model
Paraffin-embedded sections from PBOO operation without STS treatment group and PBOO operation with STS treatment groups were stained with hematoxylin and eosin and examined. The two groups of rats which had undergone PBOO procedure exhibited significant bladder detrusor hypertrophy at weeks 4 and 8. Furthermore, a progressive increase in fibrosis and loss of normal tissue architecture from week 4 to 8 was observed in the group which had not been administered STS. However, fibrosis was inhibited in the group which had been treated with STS (Fig 1).
In PBOO rats, significant detrusor muscle hypertrophy, alongside a progressive increase in fibrosis (dyed pale pink, blue arrow) and loss of normal muscle tissue (dyed purple or red, black arrow)architecture was observable at 4 and 8 weeks of PBOO. Fibrosis was inhibited in the STS group at (a) week 4 in Sham group, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, and(f) week 8 after PBOO+STS treatment. The PBOO and STS groups show detrusor hypertrophy and collagen deposition. Original magnifications, ×40.
STS attenuates progressive bladder fibrosis by suppressing the expression of excess extracellular matrix proteins
The inhibitory effects of STS on bladder fibrosis, the expression of α-SMA, collagen I and collagen III protein and their mRNA were consistently detected by western blotting, immunohistochemistry, and RT-PCR. Masson’s trichrome staining of bladder tissue sections showed the progressive increase in collagen deposition in the PBOO rats without STS treatment, however, significantly decreased in the PBOO rats with STS treatment (Fig 2). RT-PCR analysis showed that α-SMA, collagen I, and collagen III expression were decreased in PBOO rats with STS treatment rats at weeks 4 and 8 (P<0.05, n = 8; Fig 3). The western blot and immunohistochemistry findings were also consistent with that of the RT-PCR resultsmRNA expression (P<0.05, n = 8; Figs 4, 5, 6 and 7).
Collagen fibril is represented by the green staining and muscle is purple (A) Representative Masson’s trichrome–stained sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) 8 weeks after PBOO, (f) 8 weeks after PBOO+STS treatment. (B) Fibrotic area scores of the bladder tissues. Each bar represents the mean±SD of eight rats. *P<0.05 vs. Sham group (n = 8); #P<0.05 vs PBOO group. Original magnifications, ×400.
(a) Acta2 mRNA, (b) Col1a1 mRNA, (c) Col3a1 mRNA. Acta2, Col1a1 and Col3a1 mRNA expression was significantly higher in PBOO rats at weeks 4 and 8 compared with Sham rats (P<0.05, n = 8). STS treatment led to decreased Acta2, Col1a1, Col3a1 mRNA expression (P<0.05, n = 8). Each bar represents the mean±SD for eight rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group.
a-SMA, collagen I and collagen III expression was significantly higher in PBOO rats at weeks 4 and 8 compared with the Sham group (P<0.05, n = 8). Each bar represents the mean±SD of 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group.
(A) Representative a-SMA-immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. a-SMA expression was significantly higher in PBOO rats at weeks 4 and 8 compared with Sham groups (P<0.05, n = 8). STS treatment induced decreased a- SMA expression (P<0.05, n = 8). (B) Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD for 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400. IOD, integrated optical density.
(A) Representative collagen I-immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. Collagen I expression was significantly higher in PBOO rats at weeks 4 and 8 compared with the Sham groups (P<0.05, n = 8). STS treatment induced decreased collagen I expression (P<0.05, n = 8). (B) Densitometric analyses were performed from 8 independent experiments. Each bar represents the mean±SD of 8 rats. *P<0.05 vs. Sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400.
(A) Representative collagen III immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. Collagen III expression was significantly higher in the PBOO rats at weeks 4 and 8 compared with the Sham groups (P<0.05, n = 8). STS treatment induced decreased collagen III (P<0.05, n = 8). (B) Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD of 8 rats. *P<0.05 vs. Sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400.
Blockage of TGF-β/Smad activation was found to be a critical mechanism in STS prevention of bladder fibrosis in PBOO rats with STS treatment
We assessed the effects of STS on TGF-β1 (Tgfb 1) and Smad2/3 mRNA expression using real-time PCR. STS inhibited the expression of (Tgfb 1 mRNA but had no effect on Smad2 and Smad3 mRNA expression in PBOO rat bladder at weeks 4 and 8 (Fig 8). Western blot analysis revealed that STS treatment reduced the expression of TGF-β1 protein and phosphorylated Smad2/3, but not total Smad2/3 expression in PBOO rats at weeks 4 and 8 (P<0.05, n = 8, Fig 9). The immunohitochemistry experiments revealed similar results (Figs 10, 11 and 12).
Compared with the Sham group, Tgfb1, Smad2 and Smad3 mRNA expression in the PBOO group was not significantly different. Densitometric analyses were performed from 8 independent experiments. Each bar represents the mean±S.D of 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group.
Compared to the Sham group, TGF-β1 and phosphorylated Smad2/3 expression but not total Smad2/3 expression in PBOO was significantly higher at weeks 4 and 8 (P<0.05, n = 8). Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD of 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group.
(A) Representative TGF-β1-immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. TGF-β1 expression was significantly higher in the PBOO rats at weeks 4 and 8 compared with the Sham groups (P<0.05, n = 8). STS Treatment induced decreased TGF-β1 expression (P<0.05, n = 8). (B) Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD for 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400.
(A) Representative Phosphorylated Smad2-immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. Expression of Phosphorylated Smad2 was significantly higher in the PBOO rats at weeks 4 and 8 compared with the Sham groups (P<0.05, n = 8). STS Treatment induced decreased Phosphorylated Smad2 (P<0.05, n = 8). (B) Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD for 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400. IOD, integrated optical density.
(A) Representative phosphorylated Smad3-immunostained rat bladder sections. (a) Sham group at 4 weeks, (b) week 4 after PBOO, (c) week 4 after PBOO+STS treatment, (d) week 8 after Sham group, (e) week 8 after PBOO, (f) week 8 after PBOO+STS treatment. Expression of phosphorylated Smad3 was significantly higher in PBOO rats at weeks 4 and 8 compared with the Sham group (P<0.05, n = 8). STS treatment induced decreased expression of phosphorylated Smad3 (P<0.05, n = 8). (B) Densitometric analyses performed from 8 independent experiments. Each bar represents the mean±SD of 8 rats. *P<0.05 vs. sham group (n = 8); #P<0.05 vs. PBOO group. Original magnifications, ×400. IOD, integrated optical density.
Discussion
In the present study, it was observed that bladder tissue fibrosis in the PBOO model was significantly reduced at weeks 4 and 8 by intraperitoneal injection of STS a traditional herbal medicine, indicating that STS has therapeutic effects in the amelioration of bladder wall fibrosis secondary to PBOO.
Chronic obstruction of the bladder outlet due to in benign prostatic hypertrophy (BPH) leads to a number of cellular and structural alterations in the bladder wall that ultimately impair the ability of the bladder to empty or fill completely[19]. Various conditions involving neurological or outlet obstruction could give rise to the accumulation of connective and fibrotic tissues in the bladder wall [20], which in turn, cause bladder dysfunction, and can ultimately result in renal failure. The reduced bladder compliance consequent to bladder outlet obstruction results from the dysmorphogenesis, marked by myofibroblast hyperactivity and excessive ECM deposition. Excessive accumulation of collagen fibers occurs in the bladder walls of low-compliance bladders, where the total collagen has been reported to be increased by 10%, and in particular, collagen III fiber type increased by about 49% [21]. In the present study, expression of the collagen fibers in bladder wall was significantly increased after PBOO (P<0.05) when compared to the Sham group. There was a time-dependent 2-fold increase in accumulation of collagen fiber in PBOO operation without STS treatment group at week 4 when compared with week 2. On the contrary, collagen fibril expression in S PBOO operation with STS treatment group rats was significantly lower than that in the PBOO operation without STS group (P<0.05, Fig 4), indicating that STS inhibited the collagen expression secondary to PBOO. It may be inferred that STS may aid in improving bladder compliance, and thus enhance bladder function after PBOO. Among various factors, TGF-β1 is perhaps the key cytokine that plays a central role in the progression of fibrosis. Recent reports have elucidated the TGF-β1 signaling mechanism involved in the development of fibrosis in the PBOO model [5].
The active form of TGF-β1 binds to a TGF-β-specific receptor, forming an activated complex [22]. The activated TGF-β receptor complex initiates intracellular signaling by phosphorylating specific downstream proteins known as R-Smads (Smad2 and Smad3), which in turn form complexes with the common Smad (Smad4). The activated Smad complexes get translocated from the cytoplasm into the nucleus, where the activated Smads regulate the transcription of the target genes, such as those for collagen I (COL1A1) and collagen III (COL3A1) [23]. The reduced bladder compliance consequent to bladder outlet obstruction results from the dysmorphogenesis, marked by myofibroblast hyperactivity and excessive ECM deposition. In a unilateral ureteral obstruction model, a dramatic decrease in mRNA expression of TGF-beta 1 and type I collagen was demonstrated in antisense-transfected obstructed kidneys. Further, the interstitial fibrotic area of the obstructed kidneys exposed to antisense was significantly lower than that of both untreated obstructed kidneys and kidneys treated with scrambled antisense [24]. However, its role in the progress of the bladder fibrosis subsequent to PBOO remains a major topic of debate. Using a PBOO model, TGF-β1 protein expression was found to be decreased during bladder compensation, while an elevated TGF-β1 expression was reported during the decompensation stage [25]. In our study, we found that TGF-β1 expression was elevated at 4 weeks and 8 weeks, based on which it can inferred that the bladder has gradually entered the stage of decompensation at 4 weeks. However, some reports suggest that the bladder fibrosis developed in rats, 14 days after obstruction [26, 27]. In another study, higher values of TGF-β1 were observed in a rat PBOO model, and additionally, treatment with amitriptyline further aggravated the fibrotic process after infravesical obstruction [28]. Taking a cue from these studies, we assessed TGF-β1 expression in PBOO at weeks 4 and 8 using RT-PCR and western blotting. We found that the expression of TGF-β1 mRNA and protein in the PBOO operation without STS treatment group was significantly higher than that in the sham operation group (P<0.05, Fig 9). TGF-β recruits fibroblasts from the surrounding tissues, and promotes their proliferation and differentiation, thereby stimulating the synthesis of ECM, for example, connective tissues and collagen fibrils [29]. In our study, STS markedly inhibited phosphorylated Smad2/3 protein levels without altering Smad2/3 expression, suggesting that it ameliorates bladder fibrosis secondary toPBOO by blocking the TGF-β1-mediated signaling pathway in a positive feedback loop.
STS has been used to treat cardiovascular disease and various tumors [30]. The potential effects of STS treatment on the progression of fibrosis in different organs or tissues have garnered much research interest recently [31–35]. We observed that α-SMA expression was significantly increased in the PBOO operation without STS treatment group. α-SMA expression is considered specific for myoblasts that could be derived from epithelial-mesenchymal transition and such cells can induce ECM deposition[29]. In the present study, STS treatment effectively inhibited α-SMA expression and TGF-β1/Smad signaling pathway activation. It can postulated from the findings of this study that STS inhibits the expression of TGF-β1 mRNA leading to decreased activity of downstream signaling pathways. STS has also been reported to inhibit renal interstitial fibroblasts differentiation via the TGF-β1/Smad signaling pathway leading to a reduction in collagen I and collagen III deposition[31]. In other words, STS could have a role as a potential therapeutic modality for attenuating ECM synthesis in PBOO, possibly by modulating TGF-β/Smad signaling.
Conclusions
Our findings indicate that STS can delay the progression of bladder fibrosis in PBOO rats by inhibition of the TGF-β/Smad signaling cascade. The present results support the premise that STS may be a potential therapeutic choice for preventing bladder fibrosis secondary to PBOO.
Acknowledgments
This study was funded by Xuzhou Municipal Science and Technology development grant XF11C066.
Author Contributions
Conceived and designed the experiments: XJ HZ XS. Performed the experiments: XJ YC. Analyzed the data: XJ YC HZ XS PQ. Contributed reagents/materials/analysis tools: XJ YC HZ XS RC. Wrote the paper: XJ YC HZ XS PQ. Edited and revised manuscript: XJ YC BW. Approved final version of manuscript: XJ YC HZ XS BW PQ RC.
References
- 1. Baskin LS, Hayward SW, DiSandro MS, Li YW, Cunha GR. Epithelial-mesenchymal interactions in the bladder. Implications for bladder augmentation. Advances in experimental medicine and biology. 1999;462:49–61. Epub 1999/12/22. pmid:10599413.
- 2. Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, et al. Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder. BJU international. 2009;103(10):1424–1428. Epub 2008/11/08. pmid:18990142.
- 3. Imamura M, Kanematsu A, Yamamoto S, Kimura Y, Kanatani I, Ito N, et al. Basic fibroblast growth factor modulates proliferation and collagen expression in urinary bladder smooth muscle cells. American journal of physiology Renal physiology. 2007;293(4):F1007–1017. Epub 2007/07/20. pmid:17634401.
- 4. Altuntas CZ, Daneshgari F, Izgi K, Bicer F, Ozer A, Sakalar C, et al. Connective tissue and its growth factor CTGF distinguish the morphometric and molecular remodeling of the bladder in a model of neurogenic bladder. American journal of physiology Renal physiology. 2012;303(9):F1363–1369. Epub 2012/09/21. pmid:22993071; PubMed Central PMCID: PMCPMC3518188.
- 5. Islam SS, Mokhtari RB, El Hout Y, Azadi MA, Alauddin M, Yeger H, et al. TGF-beta1 induces EMT reprogramming of porcine bladder urothelial cells into collagen producing fibroblasts-like cells in a Smad2/Smad3-dependent manner. J Cell Commun Signal. 2014;8(1):39–58. pmid:24338442.
- 6. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor beta signal transduction. J Leukoc Biol. 2002;71(5):731–740. pmid:11994497.
- 7. Shi B, Zhu Y, Laudon V, Ran L, Liu Y, Xu Z. Alterations of urine tgf-beta1 and bfgf following bladder outlet obstruction: a predictor for detrusor contractibility? Urol Int. 2009;82(1):43–47. pmid:19172096.
- 8. Anumanthan G, Tanaka ST, Adams CM, Thomas JC, Wills ML, Adams MC, et al. Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. The Journal of urology. 2009;182(4 Suppl):1775–1780. Epub 2009/08/21. pmid:19692014.
- 9. Serban AI, Stanca L, Geicu OI, Munteanu MC, Costache M, Dinischiotu A. Extracellular matrix is modulated in advanced glycation end products milieu via a RAGE receptor dependent pathway boosted by transforming growth factor-beta1 RAGE-beta1. J Diabetes. 2015;7(1):114–124. pmid:24666836.
- 10. Zhou D, Li Z, Zhang L, Zhan C. Inhibitory effect of tanshinone ii a on tgf ii-beta1-induced cardiac fibrosis. J Huazhong Univ Sci Technolog Med Sci. 2012;32(6):829–833. pmid:23271281.
- 11. Tu X, Zhang H, Zhang J, Zhao S, Zheng X, Zhang Z, et al. MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway. J Pathol. 2014;234(1):46–59. pmid:24817606.
- 12.
Yoshizawa H, Morishita Y, Watanabe M, Ishibashi K, Muto S, Kusano E, et al. TGF-beta-siRNA delivery with nanoparticles inhibits peritoneal fibrosis. Gene Ther. 2015. pmid:25567535.
- 13. Chen Z, Xu H. Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis. Evid Based Complement Alternat Med. 2014;2014:267976. pmid:25525444.
- 14. Xu Y, Feng D, Wang Y, Lin S, Xu L. Sodium tanshinone iia sulfonate protects mice from cona-induced hepatitis via inhibiting nf-kappab and ifn-gamma/stat1 pathways. J Clin Immunol. 2008;28(5):512–519. pmid:18498044.
- 15. Tang J, Zhan C, Zhou J. Effects of tanshinone iia on transforming growth factor beta1-smads signal pathway in renal interstitial fibroblasts of rats. J Huazhong Univ Sci Technolog Med Sci. 2008;28(5):539–542. pmid:18846334.
- 16.
Yang L, Hu J, Hao HZ, Yin Z, Liu G, Zou XJ. Sodium tanshinone IIA sulfonate attenuates the transforming growth factor-beta1-induced differentiation of atrial fibroblasts into myofibroblasts in vitro. Int J Mol Med. 2015. pmid:25647570.
- 17. Matsumoto S, Shimizu N, Hanai T, Uemura H, Levin R. Bladder outlet obstruction accelerates bladder carcinogenesis. BJU international. 2009;103(10):1436–1439. Epub 2008/12/17. pmid:19076130.
- 18. Chunming J, Miao Z, Cheng S, Nana T, Wei Z, Dongwei C, et al. Tanshinone iia attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model. Ren Fail. 2011;33(3):355–362. pmid:21401363.
- 19. Levin RM, Longhurst PA, Monson FC, Kato K, Wein AJ. Effect of bladder outlet obstruction on the morphology, physiology, and pharmacology of the bladder. The Prostate Supplement. 1990;3:9–26. Epub 1990/01/01. pmid:1689174.
- 20. Shapiro E, Becich MJ, Perlman E, Lepor H. Bladder wall abnormalities in myelodysplastic bladders: a computer assisted morphometric analysis. The Journal of urology. 1991;145(5):1024–1029. Epub 1991/05/01. pmid:2016785.
- 21. Landau EH, Jayanthi VR, Churchill BM, Shapiro E, Gilmour RF, Khoury AE, et al. Loss of elasticity in dysfunctional bladders: urodynamic and histochemical correlation. J Urol. 1994;152(2 Pt 2):702–705. pmid:8021999.
- 22. Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: regulation of TGF-beta signaling in the kidney. Journal of the American Society of Nephrology: JASN. 2002;13(4):1126–1128. Epub 2002/03/26. pmid:11912276.
- 23. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577–584. Epub 2003/10/10. pmid:14534577.
- 24. Isaka Y, Tsujie M, Ando Y, Nakamura H, Kaneda Y, Imai E, et al. Transforming growth factor-beta 1 antisense oligodeoxynucleotides block interstitial fibrosis in unilateral ureteral obstruction. Kidney Int. 2000;58(5):1885–1892. pmid:11044208.
- 25. Buttyan R, Chen MW, Levin RM. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. European urology. 1997;32 Suppl 1:32–39. Epub 1997/01/01. pmid:9218941.
- 26. Amaro JL, Balasteghin KT, Padovani CR, Montenegro R. Structural alterations of the bladder induced by detrusor instability. experimental study in rabbits. Int Braz J Urol. 2005;31(6):579–585; discussion 586. pmid:16386129.
- 27. Rubinstein M, Sampaio FJ, Costa WS. Stereological study of collagen and elastic system in the detrusor muscle of bladders from controls and patients with infravesical obstruction. Int Braz J Urol. 2007;33(1):33–39; discussion 39–41. pmid:17335596.
- 28. de Almeida Prado PS, Soares MF, Lima FO, Schor N, Teixeira VP. Amitriptyline aggravates the fibrosis process in a rat model of infravesical obstruction. Int J Exp Pathol. 2012;93(3):218–224. pmid:22563623.
- 29. Zhang D, Sun L, Xian W, Liu F, Ling G, Xiao L, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Laboratory investigation; a journal of technical methods and pathology. 2010;90(3):436–447. Epub 2010/02/10. pmid:20142807.
- 30. Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Cardiovascular actions and therapeutic potential of tanshinone iia. Atherosclerosis. 2012;220(1):3–10. pmid:21774934.
- 31. Tang J, Zhan C, Zhou J. Effects of tanshinone IIA on transforming growth factor β1-Smads signal pathway in renal interstitial fibroblasts of rats. Journal of Huazhong University of Science and Technology [Medical Sciences]. 2008;28:539–542.
- 32. Yang L, Zou X-J, Gao X, Chen H, Luo J-L, Wang Z-H, et al. Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Experimental & molecular medicine. 2009;41(7):508–516.
- 33. Fang J, Xu S-W, Wang P, Tang F-T, Zhou S-G, Gao J, et al. Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine. 2010;18(1):58–64. pmid:20638255
- 34. Chunming J, Miao Z, Cheng S, Nana T, Wei Z, Dongwei C, et al. Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model. Renal failure. 2011;33(3):355–362. pmid:21401363
- 35. Zhang Y, Zhang Y, Xie Y, Gao Y, Ma J, Yuan J, et al. Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by Salvia miltiorrhiza. Journal of ethnopharmacology. 2013;148(2):671. pmid:23707206